Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ellipticine is a naturally occurring indole alkaloid and organic heterotetracyclic compound with potent antineoplastic activity. It acts as a DNA intercalating agent and inhibitor of topoisomerase II, leading to DNA damage and cell cycle arrest. Ellipticine is considered a prodrug that requires metabolic activation by cytochrome P450 enzymes (notably CYP1A and CYP3A), which generate reactive metabolites that form covalent DNA adducts. This results in induction of apoptosis via p53-dependent pathways and mitochondrial apoptotic mechanisms. Ellipticine has shown significant cytotoxicity against various cancer types in vitro and in vivo but has not progressed to clinical approval due to toxicity concerns such as mutagenicity[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ellipticine.